ApeX Therapeutics, a cancer-focused drug discovery and development company with technology licensed from Indiana University Research and Technology Corporation, has received a Phase I, Small Business Innovation Research grant for $240,332 from the National Cancer Institute at the National Institutes of Health to develop an oral or injectable form of medicine to more effectively treat leukemia (blood cell cancers) and other cancerous tumors in children.
Because childhood leukemia that has relapsed or is resistant to, or does not respond to, treatment is often associated with a grave prognosis, there is keen interest in research that translates into effective therapeutic strategies benefiting this population of approximately 6,000 children per year.
ApeX Therapeutics, funded in part by the Innovate Indiana Fund and the Pearl Street Venture Fund, has also identified a novel therapy for acute lymphoblastic leukemia, the most common cancer diagnosed in children according to the Centers for Disease Control and Prevention.
Read more about ApeX Therapeutics recent grant announcement.
Leave a Reply